Citadel Advisors
MCRB icon

Citadel Advisors’s Seres Therapeutics MCRB Stock Holding History

Citadel Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Sell
43,500
-16,000
-27% -$122K ﹤0.01% 10816
2026
Q1 		$528K Buy
59,500
+16,670
+39% +$195K ﹤0.01% 9169
2025
Q4 		$637K Buy
42,830
+18,500
+76% +$323K ﹤0.01% 8432
2025
Q3 		$468K Buy
+24,330
New +$388K ﹤0.01% 9289
2025
Q2 		– Sell
-1,405
Closed -$19.7K – 14030
2025
Q1 		$19.7K Sell
1,405
-2,795
-67% -$43.8K ﹤0.01% 13157
2024
Q4 		$69.8K Sell
4,200
-2,115
-33% -$34.4K ﹤0.01% 11974
2024
Q3 		$119K Sell
6,315
-230
-4% -$4.67K ﹤0.01% 10888
2024
Q2 		$94.7K Sell
6,545
-2,455
-27% -$40.9K ﹤0.01% 10993
2024
Q1 		$139K Buy
9,000
+5,865
+187% +$126K ﹤0.01% 10877
2023
Q4 		$87.8K Sell
3,135
-2,230
-42% -$58.6K ﹤0.01% 11094
2023
Q3 		$255K Sell
5,365
-5,615
-51% -$429K ﹤0.01% 9462
2023
Q2 		$1.05M Buy
10,980
+7,895
+256% +$859K ﹤0.01% 6352
2023
Q1 		$350K Buy
3,085
+2,235
+263% +$242K ﹤0.01% 9053
2022
Q4 		$95.2K Buy
850
+170
+25% +$22.8K ﹤0.01% 11290
2022
Q3 		$87K Sell
680
-185
-21% -$18.9K ﹤0.01% 11206
2022
Q2 		$59K Sell
865
-80
-8% -$6.89K ﹤0.01% 11824
2022
Q1 		$135K Sell
945
-1,845
-66% -$284K ﹤0.01% 11970
2021
Q4 		$465K Sell
2,790
-435
-13% -$69.1K ﹤0.01% 9877
2021
Q3 		$449K Buy
3,225
+1,050
+48% +$205K ﹤0.01% 10138
2021
Q2 		$1.04M Sell
2,175
-345
-14% -$146K ﹤0.01% 8280
2021
Q1 		$1.04M Buy
2,520
+180
+8% +$82.9K ﹤0.01% 8022
2020
Q4 		$1.15M Buy
2,340
+1,710
+271% +$1M ﹤0.01% 6516
2020
Q3 		$357K Sell
630
-1,435
-69% -$477K ﹤0.01% 7847
2020
Q2 		$197K Buy
+2,065
New +$181K ﹤0.01% 8541
2016
Q4 		– Sell
-755
Closed -$186K – 7604
2016
Q3 		$186K Buy
+755
New +$265K ﹤0.01% 6347

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Citadel Advisors's MCRB Position: Q2 2026 in Review

Citadel Advisors opened a new position in Seres Therapeutics (MCRB) in Q2 2026: 10,504 shares worth $82.9K. The stake represents ﹤0.01% of the portfolio and ranks #12823 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in MCRB as recently as Q4 2025.

Citadel Advisors first reported a position in MCRB in Q2 2015 and has held it in 36 quarters since. The position peaked at $8.02M in Q2 2015. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Citadel Advisors held 10,504 shares of Seres Therapeutics worth $82.9K as of Q2 2026.
  • Seres Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Seres Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12823 holding.
  • Citadel Advisors first reported a position in Seres Therapeutics in Q2 2015 and has held it in 36 quarters since.
  • Citadel Advisors's Seres Therapeutics position peaked at $8.02M in Q2 2015.
  • 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.